Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

Inclusion Criteria: * Histologically or cytologically confirmed unresectable stage III or IV cutaneous or mucosal melanoma * Presence of BRAF V600E or V600K mutation in tumor tissue prior to enrolment as per local assessment * Tumor tissue from an unresectable or metastatic site of disease must be provided for biomarker analyses. This can be an archived sample if obtained at maximum 3 months prior to randomization and if the patient did not receive treatment since then. * Measurable disease per RECIST 1.1 criteria by computed tomography (CT) or Magnetic Resonance Imaging (MRI) of Chest/Abdomen/Pelvis CT and brain CT/MRI performed within 28 days prior to randomization * Patients ≥ 18 years of age * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 * Patients must be able to swallow and retain oral tablets * Adequate organ function within 14 days prior to randomization * Patients with hyperthyroidism or hypothyroidism but that are stable on hormone replacement can be included. * Adequate cardiac function Exclusion Criteria: * Uveal melanoma * Any symptomatic brain or leptomeningeal disease. Subjects with brain metastases are eligible if these have been locally treated and there is no magnetic resonance imaging (MRI) evidence of progression for at least 4 weeks after treatment and treatment is completed within 28 days prior to first dose of study drug administration. There must also be no requirement for immunosuppressive doses of systemic corticosteroi…